UCB SA (EBR: UCB)
Belgium
· Delayed Price · Currency is EUR 183.85
+0.70 (0.38%)
Jan 21, 2025, 10:32 AM CET
UCB SA Revenue
UCB SA had revenue of 2.79B EUR in the half year ending June 30, 2024, a decrease of -2.24%. This brings the company's revenue in the last twelve months to 5.45B, up 3.32% year-over-year. In the year 2023, UCB SA had annual revenue of 5.18B, down -4.87%.
Revenue (ttm)
5.45B
Revenue Growth
+3.32%
P/S Ratio
6.38
Revenue / Employee
606.00K
Employees
9,083
Market Cap
34.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5.18B | -265.00M | -4.87% |
| Dec 31, 2022 | 5.45B | -330.00M | -5.71% |
| Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
| Dec 31, 2020 | 5.35B | 434.00M | 8.83% |
| Dec 31, 2019 | 4.91B | 281.00M | 6.07% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| argenx SE | 1.71B |
| Fagron NV | 820.76M |
| Nyxoah | 5.08M |
| Ion Beam Applications | 465.75M |
| Onward Medical | -188.00K |
| Hyloris Pharmaceuticals | 6.94M |
| Sequana Medical NV | 433.50K |
| Biocartis Group NV | 60.82M |
UCB SA News
- 5 days ago - UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx) - Benzinga
- 18 days ago - United Community Banks Inc (UCB) Announces Upcoming Fourth Quarter 2024 Financial Results Release - GuruFocus
- 6 weeks ago - United Community Banks to acquire ANB Holdings in an all-stock deal - Seeking Alpha
- 2 months ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 2 months ago - FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease - Benzinga
- 2 months ago - UCB gets FDA approval for Bimzelx for hidradenitis suppurativa - Seeking Alpha
- 2 months ago - Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - Seeking Alpha
- 2 months ago - United Community Banks: Too Rich For My Blood - Seeking Alpha